Furthermore, a recent study has shown that CX3CR1, a receptor for CX3CL1, is exclusively expressed in a subset of CD8+ effector memory T cells infiltrating tumor tissues in patients responding to anti-PD-1 therapy. Here, CD8A is linked to neoplasm.